Sarthak Satpathy

Sarthak Satpathy

Auto-generated profile, based on publicly available information

Sarthak Satpathy

Emory University, Atlanta, Georgia, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
DODenis J. Ohlstrom
Denis J. Ohlstrom
WPWilliam C. Pilcher
William C. Pilcher
MMMarina E. Michaud
Marina E. Michaud
CAChaitanya Acharya
Chaitanya Acharya
SSSarthak Satpathy
Sarthak Satpathy
MBManoj K. Bhasin
Manoj K. Bhasin
Multiple myeloma is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment (IME). To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T-cell memory after autologous stem cell transplant, whereas naïve B-cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48; P = 2.3e−4). At disease progression, multiple myeloma cells upregulated cancer–testis antigens (CTAg) and immune effector genes, with concurrent B-cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune–tumor interactions, identifying naïve B-cell reconstitution as a biomarker of durable response and CTAgs as potential targets for high-risk disease at progression. Significance: Longitudinal profiling of multiple myeloma and the IME revealed dynamic immune–tumor interactions across the disease course. Altered expression in CD8+ T cells limited memory phenotype after transplant, whereas naïve B-cell recovery associated with sustained treatment response. At progression, CTAg expression associated with immunosuppression, revealing novel mechanisms of immune dysregulation.

10 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
DODenis Ohlstrom
Denis Ohlstrom
MBMojtaba Bakhtia
Mojtaba Bakhtia
HMHope Mumme
Hope Mumme
MMMarina Michaud
Marina Michaud
FCFrank Chien
Frank Chien
MBManoj Bhasin
Manoj Bhasin
Pediatric acute myeloid leukemia (pAML) is a heterogeneous malignancy driven by diverse cytogenetic mutations. While risk stratification improved by identifying cytogenetic lesions, prognostication remains inadequate with 30% of standard-risk patients experiencing relapse within 5 years. Single-cell RNA sequencing (scRNAseq) enabled the interrogation of malignant cell heterogeneity in pAML and characterization of the immune microenvironment. Herein we report the largest pAML scRNAseq analysis to date with 708,285 cells from 164 bone marrow biopsies of 95 patients and 11 healthy controls. We uncovered treatment-resistant (TR) subtypes of pAML specific to RUNX1-RUNX1T1, FLT3-ITD, and CBFB-MYH11 patients. The enrichment of TR subtype gene signatures on the TARGET pAML data supported an association with significantly poor outcomes. Intriguingly, in addition to leukemic stem cells, we identified mast cell-like pAML associated with treatment resistance and poor outcomes. Together, immature and mature pAML subtypes are promising biomarkers for identifying patients at increased risk of relapse within cytogenetic categories.

4 March 2026
Verified
Other
Open access
PDF file
DODenis J. Ohlstrom
Denis J. Ohlstrom
WPWilliam C. Pilcher
William C. Pilcher
MMMarina E. Michaud
Marina E. Michaud
CAChaitanya Acharya
Chaitanya Acharya
SSSarthak Satpathy
Sarthak Satpathy
MBManoj K. Bhasin
Manoj K. Bhasin
Supplemental Figure 18 shows the comparison of mutations in genes for chromatin modifying proteins between samples with and without enrichment for cancer-testis antigens.

4 March 2026
Verified
Other
Open access
PDF file
DODenis J. Ohlstrom
Denis J. Ohlstrom
WPWilliam C. Pilcher
William C. Pilcher
MMMarina E. Michaud
Marina E. Michaud
CAChaitanya Acharya
Chaitanya Acharya
SSSarthak Satpathy
Sarthak Satpathy
MBManoj K. Bhasin
Manoj K. Bhasin
Supplemental Figure 17 shows the comparative rate of common myeloma cytogenetic alterations and mutations in patients with and without cancer-testis antigen enrichment.

4 March 2026
Verified
Other
Open access
PDF file
DODenis J. Ohlstrom
Denis J. Ohlstrom
WPWilliam C. Pilcher
William C. Pilcher
MMMarina E. Michaud
Marina E. Michaud
CAChaitanya Acharya
Chaitanya Acharya
SSSarthak Satpathy
Sarthak Satpathy
MBManoj K. Bhasin
Manoj K. Bhasin
Supplemental Figure 6 shows the distribution of clinical characteristics in the induction and induction with ASCT cohorts.

4 March 2026
Verified
Other
Open access
PDF file
DODenis J. Ohlstrom
Denis J. Ohlstrom
WPWilliam C. Pilcher
William C. Pilcher
MMMarina E. Michaud
Marina E. Michaud
CAChaitanya Acharya
Chaitanya Acharya
SSSarthak Satpathy
Sarthak Satpathy
MBManoj K. Bhasin
Manoj K. Bhasin
Supplemental Figure 13 shows the expression of cancer-testis antigen genes from baseline to first-progression.